Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration
May 12, 2023 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to...
Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration
May 04, 2023 16:30 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to...
Vyant Bio Announces Voluntary Nasdaq Delisting and SEC Deregistration
April 24, 2023 16:50 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to...
Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force
February 03, 2023 06:00 ET
|
Vyant Bio, Inc.
Continuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company...
Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives
January 04, 2023 16:15 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience
November 16, 2022 17:05 ET
|
Vyant Bio, Inc.
“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:...
Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
November 16, 2022 16:43 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
November 15, 2022 08:00 ET
|
Vyant Bio, Inc.
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered...
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
November 10, 2022 17:13 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16
November 10, 2022 08:00 ET
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...